Canada Inflammatory Bowel Disease Treatment Market Size & Outlook
Canada inflammatory bowel disease treatment market, 2018-2030 (US$M)
Related Markets
Canada inflammatory bowel disease treatment market highlights
- The Canada inflammatory bowel disease treatment market generated a revenue of USD 531.3 million in 2023 and is expected to reach USD 855.6 million by 2030.
- The Canada market is expected to grow at a CAGR of 7% from 2024 to 2030.
- In terms of segment, crohn's disease was the largest revenue generating type in 2023.
- Ulcerative Colitis is the most lucrative type segment registering the fastest growth during the forecast period.
Inflammatory bowel disease treatment market data book summary
| Market revenue in 2023 | USD 531.3 million |
| Market revenue in 2030 | USD 855.6 million |
| Growth rate | 7% (CAGR from 2023 to 2030) |
| Largest segment | Crohn's disease |
| Fastest growing segment | Ulcerative Colitis |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Crohn's Disease, Ulcerative Colitis |
| Key market players worldwide | AbbVie Inc, Takeda Pharmaceutical Co Ltd, Pfizer Inc, Biogen Inc, Novartis AG ADR, Eli Lilly and Co, UCB SA, Merck & Co Inc, Johnson & Johnson, Celltrion Healthcare |
Other key industry trends
- In terms of revenue, Canada accounted for 2.6% of the global inflammatory bowel disease treatment market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. inflammatory bowel disease treatment market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 855.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inflammatory Bowel Disease Treatment Market Scope
Inflammatory Bowel Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada inflammatory bowel disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inflammatory bowel disease treatment market will help companies and investors design strategic landscapes.
Crohn's disease was the largest segment with a revenue share of 60.59% in 2023. Horizon Databook has segmented the Canada inflammatory bowel disease treatment market based on crohn's disease, ulcerative colitis covering the revenue growth of each sub-segment from 2018 to 2030.
In November 2022, USD 1 million grant was provided by the Canadian Inflammatory Bowel Disease Research Consortium for increasing clinical research in the country to improve quality of life of IBD patients.
Canada-based companies, such as Giiant Pharma, Inc., are being provided USD 500,000 by the U.S. Crohn’s and Colitis Foundation for developing GT-2108 for severe and moderate ulcerative colitis. The most commonly used biologics in the country are Humira and Remicade. This provides boost to international players such as AbbVie and Janssen Biotech, Inc.
Reasons to subscribe to Canada inflammatory bowel disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada inflammatory bowel disease treatment market databook
-
Our clientele includes a mix of inflammatory bowel disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada inflammatory bowel disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Canada inflammatory bowel disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Canada inflammatory bowel disease treatment market size, by type, 2018-2030 (US$M)
Canada Inflammatory Bowel Disease Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
